US 9,637,478 B2Granted

Antiviral compounds and uses thereof

AssigneeAbbVie Inc.

InventorsDavid A. Betebenner, John K. Pratt, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Kenton L. Longenecker, Clarence J. Maring, John T. Randolph, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Dachun Liu

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Claims26

Dependent claims

A compound or salt thereof, wherein:

the compound corresponds in structure to formula (I-L0):
R1 is selected from the group consisting of:
and benzoyl;
n is selected from the group consisting of 1, 2, and 3;
R15 is selected from the group consisting of hydrogen, amino, and amino substituted with alkoxycarbonyl;
m is selected from the group consisting of 0, 1, 2, and 3;
R16 is selected from the group consisting of hydrogen, aryl, alkyl, and alkyloxycarbonyl;
R2 is selected from the group consisting of alkyl and 5-6-membered heterocyclyl, wherein:
(a) the alkyl optionally is substituted with one or more halo, and
(b) the heterocyclyl optionally is substituted with up to three substituents independently selected from the group consisting of alkyl and oxo;
R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, amino, and halo;
R4 is a fused 2-ring carbocyclyl optionally substituted with one or more substituents independently selected from the group consisting of RE, RF, and RJ;
each RE is independently selected from the group consisting of hydroxy and oxo;
each RF is C1-C6alkyl optionally substituted with one or more amino, wherein the amino optionally is substituted with one or two C1-C6alkylsulfonyl, wherein the amino portion of the alkylsulfonylamino optionally is substituted with C1-C6alkyl;
and
each RJ is C1-C6alkylsulfonylamino.

13 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/141,556Filed 28 Apr 2016 · continuation
Priority: 25 Mar 2009
Published: US 2016/0368905 A122 Dec 2016
Granted: 2 May 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification32 codes

C07D 409/10
Containing two hetero rings: linked by a carbon chain containing aromatic rings
A61K 31/18
Amides, e.g. hydroxamic acids: sulfonamides
A61K 31/27
Esters, e.g. nitroglycerine, selenocyanates: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
A61K 31/402
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: 1-aryl substituted,…

Family

Application61/163,155Us provisional application · filed 25 Mar 2009
PCT/US2010/028560Parent of this division · filed 25 Mar 2010
Application14/260,504Parent of this continuation · filed 24 Apr 2014
US 8,748,443 B2Parent of this division · filed 10 Jun 2014
US 2016/0368905 A1Pre-grant publication · published 22 Dec 2016
US 9,353,091 B2Parent of this continuation
Application13/260,199Parent of this division
Application14/260,504Parent of this division
US 2012/0082646 A1Published application
US 2015/0056164 A1Published application
US 9,637,478 B2This patent

From the US filing history. Foreign family members aren’t listed.